News

RBP-6000 is an investigational once-monthly injectable buprenorphine formulation in the ATRIGEL delivery system for the treatment of adults with moderate-to-severe OUD, as part of a complete treatment plan

The objective of the Elaris EM­III and Elaris EM­IV extension studies was to assess the long-term safety and efficacy of elagolix for the management of endometriosis with associated pain..

In 1984, the partnership had formed Kirin-Amgen to fund the global development of Epogen (epoetin alfa). Later, Kirin-Amgen also involved in the development of Neupogen, Neulasta (pegfilgrastim), Aranesp

The merger will result in a combined company, Vaxart, Inc., focused on developing orally-delivered therapeutics and prophylactics to address a variety of viral infections. “We are thrilled with

Under Voyager’s Collaboration Agreement with Sanofi Genzyme, Sanofi Genzyme had an exclusive option for ex-U.S. development and commercial rights to VY-AADC. Based on Voyager’s understanding that because this

MCL represents 3% to 10% of all non-Hodgkin lymphoma cases in the US, as per the National Cancer Institute at the National Institutes of Health. Calquence functions by

This approval follows a FDA Priority Review and is based on data from EINSTEIN CHOICE, the only clinical study to find that a Factor Xa inhibitor, specifically XARELTO,

The license agreement permits Lannett to manufacture and market in the U.S. its generic thalidomide product as of August 1, 2019 or earlier under certain circumstances.  As mandated

The transaction is expected to help Novartis with near-term product launches along with the addition of a new technology platform with potential applications in various oncology early development